BioXCell的中和/阻断抗体受到国内外研究者的普遍热爱和青睐，在肿瘤、癌症等方面的研究中广受好评。BioXCell公司位于美国新罕布什尔州，具有25年以上单克隆抗体和重组蛋白的生产及定制经验，可提供高纯度、低内毒素、无防腐剂、适用于体内临床前研究的单克隆抗体。
 | 高纯度、低内毒素，无防腐剂，适用于体内临床前研究 |
| 超过二十五年单克隆抗体和重组蛋白生产及定制经验 |
| 性价比高，可提供100mg甚至50g的大包装 |
| 超过15000篇高质量期刊文献引用 |
肿瘤癌症免疫治疗应用
●抑制免疫检查点和其他免疫调节来治疗恶性肿瘤是现在利用免疫系统杀死肿瘤细胞的有力途径。BioXCell提供三种不同克隆号的anti mouse PD-1抗体：RMP1-14、29F.1A12和J43。三种抗体都通过相同的机制发挥作用—它们结合PD-1，并在空间上阻断PD-1与PD-1配体的结合，从而阻断PD-1信号传导。这三种克隆号的抗体都非常适合在小鼠体内模型中阻断PD-1信号传导，并有大量文献支持这一应用。这些抗体之间的差异在于文献报道中的其他应用、Isotype和来源。
●通过用阻断PD-L1和它的受体PD-1之间的相互作用的抗体治疗，肿瘤生长可以暂时被抑制。
●抗PD-1联合抗CTLA-4抗体介导的免疫治疗对黑色素瘤、肾细胞癌和非小细胞肺癌具有显著疗效。
●通过靶向调节免疫反应的途径，如RANK途径，可以将“cold”肿瘤转化为“hot”肿瘤。使用Bio X Cell’s Anti-mouse RANKL (clone IK22/5) antibody，研究人员证明了对RANK通路的抑制将“cold”乳腺肿瘤转化为“hot”肿瘤，变为“hot”的肿瘤可能受益于免疫疗法。
肿瘤研究相关的抗体
| 抗体指标 | 应用 | 克隆号 | InVivoMab | InVivoPlus | 同型对照 | 稀释液 |
| Anti mouse PD-1(CD279) | In vivo blocking of PD-1/PD-L signaling | RMP1-14 | BE0146 | BP0146 | BE0089 | IP0070 |
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
IHC-Fr/Immunofluorescence/WB/FC | 29F.1A12 | BE0273 | BP0273 | BE0089 | IP0070 |
|
|
In vivo blocking of PD-1/PD-L signaling
In vitro PD-1 neutralization
WB | J43 | BE0033-2 | BP0033-2 | BE0091 | IP0065 |
|
|
| Anti mouse PD-L1(B7-H1) | In vivo PD-L1 blockade
IHC-Fr/Immunofluorescence/WB/FC | 10F.9G2 | BE0101 | BP0101 | BE0090 | IP0065 |
|
| Anti mouse CTLA-4 (CD152) | In vivo CTLA-4 neutralization
WB | 9D9 | BE0164 | BP0164 | BE0086 | IP0070 |
|
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB | 9H10 | BE0131 | BP0131 | BE0087 | IP0070 |
|
|
In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB/FC | UC10-4F10-11 | BE0032 | BP0032 | BE0091 | IP0065 |
|
|
| Anti mouse CD4 | In vivo CD4+ T cell depletion
WB/FC | GK1.5 | BE0003-1 | BP0003-1 | BE0090 | IP0065 |
|
| Anti mouse CD8α | In vivo CD8+ T cell depletion
Immunofluorescence/WB/FC | 53-6.7 | BE0004-1 | BP0004-1 | BE0089 | IP0065 |
|
In vivo CD8+ T cell depletion
WB | 2.43 | BE0061 | BP0061 | BE0090 | IP0070 |
|
In vivo CD8+ T cell depletion
WB | YTS 169.4 | BE0117 | BP0117 | BE0090 | IP0070 |
|
| Anti mouse Ly6G | In vivo neutrophil depletion
In vivo MDSC depletion
IHC-P/IHC-Fr/IF/FC | 1A8 | BE0075-1 | BP0075-1 | BE0089 | IP0065 |
|
|
| Anti mouse Ly6G/Ly6C (Gr-1) | In vivo depletion of Gr-1+ myeloid cells
IHC-P/IHC-Fr/FC | RB6-8C5 | BE0075 | BP0075 | BE0090 | IP0070 |
|
| Anti mouse IFNγ | In vivo IFN-γ neutralization
In vitro IFN-γ neutralization
ELISPOT/WB/FC | XMG1.2 | BE0055 | BP0055 | BE0088 | IPT080 |
|
|
| Anti mouse IFNAR-1 | In vivo IFNAR-1 blockade
In vitro IFNAR-1 blockade
WB | MAR1-5A3 | BE0241 | BP0241 | BE0083 | IP0070 |
|
|
Anti-mouse/human/rat/monkey/hamster/ canine/bovine TGF-β | In vivo TGF-β neutralization
In vitro TGF-β neutralization
WB | 1D11.16.8 | BE0057 | BP0057 | BE0083 | IP0070 |
|
|
| Anti mouse CD28 | In vitro T cell stimulation/activation
In vivo CD28 blockade | 37.51 | BE0015-1 | / | BE0087 | IPT060 |
|
| in vitro T cell stimulation/activation | PV-1 | BE0015-5 | / | BE0091 | IP0070 |
| Anti mouse CD3ε | In vitro T cell stimulation/activation
In vivo T cell depletion
Immunofluorescence/WB/FC | 145-2C11 | BE0001-1 | BP0001-1 | BE0091 | IP0070 |
|
|
| Anti-human CD3 | In vitro T cell stimulation/activation
In vivo T cell depletion in humanized mice
Ex vivo T cell inhibition for xenografts
FC | OKT-3 | BE0001-2 | / | BE0085 | IP0070 |
|
|
|
| Anti mouse CD40 | In vivo CD40 activation
In vitro B cell stimulation/activation | FGK4.5/ FGK45 | BE0016-2 | BP0016-2 | BE0089 | IP0070 |
|
| Anti mouse CD154 (CD40L) | In vivo blocking of CD40/CD40L signaling
In vitro blocking of CD40/CD40L signaling
WB | MR-1 | BE0017-1 | BP0017-1 | BE0091 | IP0070 |
|
|
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion
FC | PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
|
| Anti mouse IL-4 | In vivo IL-4 neutralization
In vitro IL-4 neutralization
In vivo IL-4 receptor stimulation (as a complex with IL-4)
FC/WB | 11B11 | BE0045 | BP0045 | BE0088 | IP0070 |
|
|
|
| Anti mouse NK1.1 | In vivo NK cell depletion
FC | PK136 | BE0036 | BP0036 | BE0085 | IP0070 |
|
| Anti mouse CSF1R (CD115) | In vivo macrophage depletion
In vitro CSF1R neutralization
In vivo monocyte depletion
FC/WB | AFS98 | BE0213 | BP0213 | BE0089 | IP0070 |
|
|
|
| Anti mouse CD25 (IL-2Rα) | In vivo regulatory T cell depletion
FC | PC-61.5.3 | BE0012 | BP0012 | BE0088 | IP0070 |
| anti-mouse OX40 (CD134) | In vivo OX40 activation
In vitro OX40 activation
WB | OX-86 | BE0031 | BP0031 | BE0088 | IP0070 |
|
|
畅销同型对照抗体
| 同型对照 | InVivoMab | InVivoPlus |
| 目录号 | 目录号 |
| Rat IgG2a Isotype control, FC | BE0089 | BP0089 |
| Rat IgG2b Isotype control | BE0090 | BP0090 |
| Mouse IgG1 Isotype control | BE0083 | BP0083 |
| Rat IgG1 Isotype control | BE0088 | BP0088 |
| Mouse IgG2a Isotype control | BE0085 | BP0085 |
| Mouse IgG2b Isotype control | BE0086 | BP0086 |
| Polyclonal Armenian Hamster IgG | BE0091 | BP0091 |
InVivoPlus™ Vs InVivoMab™系列之间区别
| InVivoMab | InVivoPlus |
| 纯度 | > 95% | > 95% |
| 蛋白完整性 | √ (verified via SDS-PAGE) | √ü(verified via SDS-PAGE) |
| 内毒素浓度 | < 2EU/mg | < 1EU/mg |
| 不含叠氮化物和载体蛋白 | √ | √ |
| 是否适用于体内研究 | √ | √ |
| 是否提供大包装 | √ | √ |
| 是否经WB, FC或ELISA验证 |
| √ |
| 经验证蛋白聚集≤ 5% |
| √ |
| 是否经过鼠科病原体检测 |
| √ |
| 产品货号 | BE-开头 | BP-开头
|
BioXCell的RecombiMAb系列抗体
BioXCell的RecombiMAb系列抗体是新开发的重组单克隆抗体，具有与其传统克隆号来源相同的抗原结合可变区，但IgG恒定区已从大鼠或仓鼠IgG变为小鼠或人IgG。这意味着对于小鼠模型或人源化小鼠模型的免疫原性降低。
RecombiMAb单克隆抗体
| 产品名称 | 宿主 | 亚型 | 货号 | 同型对照 | 稀释液 | 应用 |
| Anti-Mouse PD-1 (CD279) (D265A) | Mouse | IgG2a, Κ | CP151 | CP150 | IP0070 | in vivo blocking of PD-1/PD-L signaling |
| Anti-Mouse CTLA-4 (CD152) | Mouse | IgG1, Κ | CP146 | BP0083 | IP0070 | In vivo CTLA-4 neutralization
In vitro CTLA-4 neutralization
WB |
| Human IgG4 (S228P) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4, Κ | CP147 | - | - | - |
| Human IgG4 S228P L235E P329G (SPLEPG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG4 | CP148 | - | - | - |
| Human IgG1 (LALA-PG) Isotype Control, Anti-Hen Egg Lysozyme | Human | IgG1 | CP149 | - | - | - |
| Mouse IgG2a (D265A) Isotype Control, Anti-Hen Egg Lysozyme | Mouse | IgG2a | CP150 | - | - | - |
BioXCell的重组融合蛋白
融合蛋白即通过将细胞表面受体的结合域与抗体的Fc部分结合而形成，这样可以使得配体分子不会结合到内源性受体，从而阻断受体信号的传导。蛋白纯度大于95%，内毒素水平超低，不含防腐剂、稳定剂和载体蛋白等试剂，专为体内研究而开发。
| 货号 | 产品名称 | 货号 | 产品名称 | 规格 |
| BE0099 | InVivoMAb recombinant CTLA-4-lg | BP0099 | InVivoPlus recombinant CTLA-4-Ig | 5mg，25mg，50mg，100mg |
| BE0098 | InVivoMAb recombinant Flt-3L-lg | BE0148 | InVivoMAb recombinant Mouse Angiosestatin-lg | 5mg，25mg，50mg，100mg |
| BE0149 | InVivoMAb recombinant Mouse Endostatin-lg | - | - | 5mg，25mg，50mg，100mg |
产品图片：
更多详情请咨询 Bioxcell一级代理商-公海赌赌船官网登录网址
全国服务热线: 4006-800-892 邮箱: market@qibantuliao.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：020-87615159 香港: 852-69410778
代理品牌网站: www.qibantuliao.com
自主品牌网站: www.neobiosescience.net